01 January 2008
Therapeutic drug monitoring of tacrolimus
P. WallemacqAnn Transplant 2008; 13(1): 25-25 :: ID: 880179
Abstract
The purpose of this work is to summarize the current trends in tacrolimus (TAC) optimisation in transplant patients. Knowledge of the analytical method used to monitor TAC is mandatory (cross-reactivity, interferences, calibration bias, reproducibility, sensitivity, ...). Even more important is the ability to draw comparison among the different methods available (patients outcome according to TAC blood levels, multicenter clinical trials, ...). The choice of the analytical method should depend upon each laboratory characteristics (number of samples, staff experience, equipment, ...), and on the experience of clinicians with a particular method. Even though the vast majority of laboratories use immunoassays, implementation of LC-MS(MS) is increasing (2% in 1999, 19% in 2007). A large discussion exists about the most accurate approach to evaluate drug exposure or AUC (single time point -C0 or others-, limited sampling strategy or Bayesian estimates, ...). Most multi-centre trials (e.g. SYMPHONY study) stress the importance of concomitant therapies, time post-transplantation and transplant type, in defining appropriate TAC target concentrations. Recent data suggest a reduction in the recommended target TAC concentration down to 3-7 ng/mL when the drug is associated to daclizumab, MMF and steroids. Treatment management should also most likely take advantage of integrating the genetic polymorphism of proteins or enzymes involved in the tacrolimus drug disposition, in order to reach earlier optimal dosage regimen. TAC blood concentrations clearly correlate with the risk of side effects, whereas the relationship with efficacy seems much weaker. Research protocols are currently ongoing precisely to improve the predictability of the treatment efficacy (pharmacodynamic markers, drug concentration within target tissue, ...).
Keywords: cross-reactivity, biothecnology, proteomes
In Press
08 Mar 2024 : Original article
Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...Ann Transplant In Press; DOI: 10.12659/AOT.943532
14 Mar 2024 : Original article
Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort StudyAnn Transplant In Press; DOI: 10.12659/AOT.943652
14 Mar 2024 : Case report
Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...Ann Transplant In Press; DOI: 10.12659/AOT.942358
15 Mar 2024 : Review article
Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighti...Ann Transplant In Press; DOI: 10.12659/AOT.941185
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860